Skip to content
OpenCapital
Get started

Dianthus Therapeutics DNTH Cash ratio

Cash ratio at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
0.4×-0.3×
Amgen logo
AmgenAMGN
0×0.0×
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
1.1×+0.5×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
2.3×+0.8×
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
5.6×+1.6×
TG Therapeutics logo
TG TherapeuticsTGTX
2.4×+1.5×

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Where this comes from

Calculated from Dianthus Therapeutics’s reported figures.

cash and equivalents/total current liabilities=16.4×

Based on the most recent quarter.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's cash ratio?
Dianthus Therapeutics (DNTH) reported cash ratio of 16.4× in Q1 2026.
How has Dianthus Therapeutics's cash ratio changed year-over-year?
Dianthus Therapeutics's cash ratio increased by 2647.7% year-over-year, from 0.6× to 16.4×.
What is the long-term trend for Dianthus Therapeutics's cash ratio?
Over 5 years (2020 to 2025), Dianthus Therapeutics's cash ratio has grown at a -20.0% compound annual growth rate (CAGR), from 5.1× to 1.7×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.